<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87502">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01966003</url>
  </required_header>
  <id_info>
    <org_study_id>20120265</org_study_id>
    <secondary_id>2013-000738-36</secondary_id>
    <nct_id>NCT01966003</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare the effectiveness and safety of ABP 215
      against bevacizumab in men and women with advanced non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 19 weeks</time_frame>
    <description>The actual endpoint is best response seen during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 19 weeks</time_frame>
    <description>The actual endpoint is best response seen during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 19 weeks</time_frame>
    <description>Assessed at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>up to 19 weeks</time_frame>
    <description>Assessment following therapy with either ABP 215 or bevacizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent serious adverse events</measure>
    <time_frame>up to 19 weeks</time_frame>
    <description>Assessment following therapy with either ABP 215 or bevacizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies</measure>
    <time_frame>up to 45 weeks</time_frame>
    <description>Assessment following therapy with either ABP 215 or bevacizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment following therapy with either ABP 215 or bevacizumab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">642</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>ABP 215</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel followed by carboplatin to be administered on the same day and after infusion of ABP 215 for up to 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel followed by carboplatin to be administered on the same day and after infusion of bevacizumab for up to 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC 6 IV, (in the vein)</description>
    <arm_group_label>ABP 215</arm_group_label>
    <arm_group_label>bevacizumab</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>200 mg/m2, IV (in the vein)</description>
    <arm_group_label>ABP 215</arm_group_label>
    <arm_group_label>bevacizumab</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP 215</intervention_name>
    <description>15 mg/kg, IV (in the vein)</description>
    <arm_group_label>ABP 215</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>15 mg/kg, IV (in the vein)</description>
    <arm_group_label>bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-squamous non-small cell lung cancer

          -  Subjects must be initiating first-line carboplatin/paclitaxel chemotherapy within 8
             days after randomization and expected to receive at least 4 cycles of chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1

        Exclusion Criteria:

          -  Small cell lung cancer (SCLC) or mixed SCLC and NSCLC

          -  Central nervous system (CNS) metastases

          -  Malignancy other than NSCLC

          -  Palliative radiotherapy for bone lesions inside the thorax

          -  Prior radiotherapy of bone marrow

          -  Known to be positive for hepatitis B surface antigen (HbsAg), hepatitis C virus
             (HCV), or human immunodeficiency virus (HIV)

          -  Life expectancy &lt; 6 months

          -  Woman of child-bearing potential who is pregnant or is breast feeding or who is not
             consenting to use highly effective methods of birth control during treatment and for
             an additional 6 months after the last administration of the protocol specified
             treatment

          -  Man with a partner of childbearing potential who does not consent to use highly
             effective methods of birth control during treatment and for an additional 6 months
             after the last administration of the protocol specified treatment

          -  Subject has known sensitivity to any of the products to be administered during the
             study, including mammalian cell derived drug products

          -  Other inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <state>Veliko Turnovo</state>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 28, 2016</lastchanged_date>
  <firstreceived_date>October 4, 2013</firstreceived_date>
  <firstreceived_results_disposition_date>March 8, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
